Microbiome Immunotherapy Neoadjuvant Assessment

Predictive biomarkers of response to combination chemotherapy and immune-checkpoint inhibitors are urgently needed to help tailor treatment recommendations for patients with early-stage TNBC. Tumour-associated microbiota in primary breast tumours represent promising and novel candidate biomarkers modulators of the efficacy of therapies for patients with TNBC. It has been shown that microbes colonizing breast tumours can modulate the efficacy of commonly used drugs and that the microbiome of breast tissue biopsies could represent a new biomarker. Data on the microbiome of patients with cancer indicate the potential for a new class of bacteria-based oncological biomarkers, for exploitation in precision oncology.

NCT Number	NCT06709651
Lead Sponsor	University College Cork Collaborators: Breast Cancer Research Foundation
Conditions	Triple Negative Breast Cancer
Enrollment	30 participants
Start Date	2024-10-02
Primary Completion	2026-11 (estimated)
Study Completion	2027-11 (estimated)
Updated on ClinicalTrials.gov	2026-03-04